The US Food and Drug Administration (FDA) has approved the Amplatzer Piccolo Occluder (Abbott), the first medical device to treat patent ductus arteriosus (PDA) in premature babies weighing as little ...
A PDA requiring treatment is present in approximately 20% of premature infants 1 ABBOTT PARK, Ill., Dec. 18, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has received U.S. Food and Drug ...
Add Yahoo as a preferred source to see more of our stories on Google. Abbott’s range of paediatric heart treatments also includes the Masters HP 15mm mechanical heart valve. Credit: Michael Vi / ...
Chicago-based Abbott Laboratories received an FDA approval for the Amplatzer Piccolo Occluder to treat patent ductus arteriosus (PDA), a condition in which a newborn has a persistent opening in the ...
Abbott’s range of entries to Fast Company’s 2o20 World Changing Ideas Awards made it our selection for World Changing Company of the Year. While the company is currently a major player in helping ramp ...
Abbott announced the US Food and Drug Administration (FDA) approved the Amplatzer Piccolo Occluder, the world's first medical device that can be implanted in the tiniest babies (weighing as little as ...
First and only delivery system designed specifically for premature infants with a patent ductus arteriosus (PDA), a life-threatening opening in their heart New delivery system enables precise ...
ABBOTT PARK, Ill., Dec. 18, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has received U.S. Food and Drug Administration (FDA) clearance and CE Mark for its Amplatzer Piccolo™ Delivery ...
First and only delivery system designed specifically for premature infants with a patent ductus arteriosus (PDA), a life-threatening opening in their heart New delivery system enables precise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results